Clinical Trials Logo

Thrombocytopenia clinical trials

View clinical trials related to Thrombocytopenia.

Filter by:

NCT ID: NCT05130424 Recruiting - Carcinoma;Blood Clinical Trials

A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

Start date: September 29, 2021
Phase:
Study type: Observational

To observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in Henan Province

NCT ID: NCT05126004 Not yet recruiting - Clinical trials for Stem Cell Transplant Complications

AZA Combined With NAC for PIT After HSCT

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC) was the most commonly used antioxidant. Therefore, the investigators have been wondering whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the possible mechanism of it.

NCT ID: NCT05124028 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

A Study of Orelabrutinib in Patients With ITP

Start date: December 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

NCT ID: NCT05116423 Recruiting - Clinical trials for Immune Thrombocytopenia

Prediction Model for Critical ITP Bleeds in Primary Immune Thrombocytopenia Inpatients

Start date: November 10, 2021
Phase:
Study type: Observational

This study developed the first prediction model for risk of critical ITP bleeds for ITP inpatients using a novel machine learning algorithm. This model has been implemented as a web-based model so that clinicians can obtain the estimated probability of critical ITP bleeds for ITP inpatients. The objective of this study is to prospectively and externally validate the risk of critical ITP bleeds in newly admitted ITP patients.

NCT ID: NCT05102370 Recruiting - Clinical trials for Clonal Cytopenia of Undetermined Significance

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Start date: October 6, 2021
Phase: Phase 1
Study type: Interventional

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

NCT ID: NCT05095896 Completed - Clinical trials for Immune Thrombocytopenia

The Serum Lipid Profiles in ITP: a Retrospective Study

Start date: January 1, 2018
Phase:
Study type: Observational

The project was retrospectively undertaking by Qilu Hospital of Shandong University in China. In order to investigate the correlations between platelet indices, serum lipids and bleeding symptoms in ITP.

NCT ID: NCT05095844 Not yet recruiting - COVID-19 Clinical Trials

National Vaccine Adverse Event Reporting Survey and Etiology

NVAERS
Start date: December 1, 2021
Phase:
Study type: Observational

The primary goal of this study is to create a national database and gather vaccine-associated serious adverse events/injury data from newly vaccinated individuals in the US in order to identify the possible underlying causal relationships and plausible underlying biological mechanisms. The secondary goal is to establish criteria that enable classification of vaccine-induced adverse events/injuries compare data from our database with the official Vaccine Injury Table National Vaccine Injury Compensation Program on or after March 21, 2017. The tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.

NCT ID: NCT05087459 Recruiting - Thrombocytopenia Clinical Trials

Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma

Start date: June 30, 2021
Phase:
Study type: Observational

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, accounting for the second leading cause of cancer death in China.Surgical treatment of hepatocellular carcinoma is the most important means for long-term survival of patients with hepatocellular carcinoma, including hepatectomy and liver transplantation.Chronic liver disease caused by hepatitis B infection is the main pathogenic factor of liver cancer in China. Meanwhile, nearly 80% of patients with hepatocellular carcinoma are complicated with cirrhosis, and the incidence of thrombocytopenia in patients with cirrhosis is reported to be as high as 78%.Many previous studies have found that thrombocytopenia is closely related to perioperative outcome of hepatocellular carcinoma.The purpose of this study was to evaluate the efficacy and safety of avatripopa in the treatment of thrombocytopenia in patients with primary hepatocellular carcinoma undergoing elective hepatectomy and its effect on perioperative outcome.

NCT ID: NCT05086744 Not yet recruiting - Clinical trials for Immune Thrombocytopenia (ITP)

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Start date: November 29, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

NCT ID: NCT05070845 Not yet recruiting - Clinical trials for Primary Immune Thrombocytopenia

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Start date: November 15, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, single arm, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (>3 months and ≤12 months), or chronic (>12 months) ITP